

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

NCT05548283

Status	RECRUITING
Phase	Phase 4
Sponsor	Chris Goss
Enrollment	730 participants

Key Eligibility Criteria

Inclusion (4)

- All genders ≥ 6 years of age at Visit 1
- Documentation of a CF diagnosis
- Clinician intent to treat index CF PEx with a planned 14-day course of IV antimicrobials
- At least one documented Pa positive culture within two years prior to Visit 1

Exclusion (6)

- Participant is not pregnant
- No known renal impairment or history of solid organ transplantation
- No IV antimicrobial treatment, ICU admission, pneumothorax, or hemoptysis within 6 weeks prior to Visit 1
- No use of investigational therapies, new CF transmembrane conductance regulator (CFTR) modulators, or treatment for Nontuberculous mycobacteria (NTM) within 4 weeks prior to Visit 1
- No history of hypersensitivity, vestibular, or auditory toxicity with aminoglycosides
- ... and 1 more (see full listing online)

Locations (60 total)

The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama, United States
Tucson Cystic Fibrosis Center, Tucson, Arizona, United States
University of California San Diego, La Jolla, California, United States
... and 57 more locations